Wipfli Financial Advisors’s Myriad Genetics MYGN Stock Holding History

Wipfli Financial Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$7K	Buy	+379	New	+$8.7K	﹤0.01%	1973

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Wipfli Financial Advisors's MYGN Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Myriad Genetics (MYGN) in Q3 2022: 379 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #1973 among its holdings.

191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

Wipfli Financial Advisors held 379 shares of Myriad Genetics worth $7K as of Q3 2022.
Myriad Genetics was a new Wipfli Financial Advisors position in Q3 2022.
Myriad Genetics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1973 holding.
191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.